GENEVA and RECIFE, BRAZIL--(Marketwire - July 21, 2008) - Children infected by Chagas disease, endemic in 21 countries in Central and South America, will soon have access to a treatment tailored to their needs. As a result of the new partnership between Lafepe and DNDi, the first pediatric formulation of benznidazole will be made available to patients by the end of 2009. The drug will be sold at cost, with no profit to the institutions involved in its development, and will be available for distribution worldwide.